Stock Pulse
Incyte (INCY) reported Q4 2024 revenue exceeding expectations, driven by Jakafi and Opzelura, but missed EPS estimates, leading to a 20.5% stock drop [2]. While full-year 2024 revenue grew 15% [2], concerns remain about profitability and growth compared to competitors [2], [6]. Phase 3 trial results for povorcitinib were mixed, raising questions about its market potential [4]. Incyte announced a collaboration with Genesis Therapeutics to leverage AI in drug discovery [7] and the launch of Minjuvi in Mexico through a licensing agreement with Knight Therapeutics [5]. The company will release Q1 2025 financial results on April 29th [1], with a positive Earnings Surprise Prediction of 9.01% [8]. Despite some positive developments, declining operating margins and return on invested capital highlight financial challenges [6].